KBI Biopharma Acquires Merck's Biologics Operations - - BioPharm International

ADVERTISEMENT

KBI Biopharma Acquires Merck's Biologics Operations



KBI Biopharma (KBI), a contract development and manufacturing organization, has signed an agreement with Merck & Co., to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.

KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

Source: KBI Biopharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here